Drug

Prednisone

Approved · FDA

ClassGlucocorticoid receptor agonistEmerging researchLate-stage developmentSteady momentum

Also known as Dehydrocortisone, Deltasone, Liquid Pred, Metacortandracin+12 more

Dehydrocortisone, Deltasone, Liquid Pred, Metacortandracin, Meticorten, Orasone, Prednicen-M, Prednicot, Rayos, Sterapred, Sterapred DS, Prednisona, 1, 2-Dehydrocortisone, 1,2-Dehydrocortisone, 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione, Prednisonum.

RxNorm8640 ChEMBLCHEMBL635 ATCA07EA03 ATCH02AB07UNIIVB0R961HZT

Research papers

Active clinical trials

Glucocorticoid receptor

Primary target

Regulatory events

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Phase 2 Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL

Clinical trial2026-07-31Primary completion · ClinicalTrials.gov

A Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL)

Clinical trial2026-07-30Results expected Q4 2027 · ClinicalTrials.gov

A Phase 2 Study of SNDX-5613 in Combination With Chemotherapy for Patients With Relapsed or Refractory KMT2A-Rearranged Infant Leukemia

Clinical trial2026-07-16Results expected Q4 2027 · ClinicalTrials.gov

A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010)

Clinical trial2026-07-16Results expected Q3 2029 · ClinicalTrials.gov

Approval: PREDNISONE (ANDA218035)

Regulatory2026-06-26FDA

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.

Research2025-10-07Nature medicine

Label change: PREDNISONE (ANDA080352)

Regulatory2024-06-05FDA

Label change: PREDNISONE (ANDA080352)

Regulatory2024-05-16FDA

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.

Research2021-12-14The New England journal of medicine

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.

Research2019-09-30The New England journal of medicine

Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination.

Research2017-11-15Journal of neurology, neurosurgery, and psychiatry

Label change: PREDNISONE (ANDA080352)

Regulatory2008-11-24FDA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Prednisone

Aliases & brands

DehydrocortisoneDeltasoneLiquid PredMetacortandracinMeticortenOrasonePrednicen-MPrednicotRayosSterapredSterapred DSPrednisona1, 2-Dehydrocortisone1,2-Dehydrocortisone17,21-Dihydroxypregna-1,4-diene-3,11,20-trionePrednisonum

RxNorm CUI

8640

ChEMBL ID

CHEMBL635

ATC codes

A07EA03H02AB07

UNII

VB0R961HZT

Primary mechanism

Glucocorticoid receptor agonist

Regulatory jurisdictions

fda

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Glucocorticoid receptor

NR3C1 · P04150

AGONISTGlucocorticoid receptor agonist

Regulatory timeline

24 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval

1972-04-21

Latest approval

2026-06-26

Authorities

FDA

Total events

fdaU.S. Food and Drug Administration· 24 events

2026-06-26Approval

Approval: PREDNISONE (ANDA218035)

Evidence ↗

2024-06-05Label change

Label change: PREDNISONE (ANDA080352)

Evidence ↗

2024-05-16Label change

Label change: PREDNISONE (ANDA080352)

Evidence ↗

Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).

Clinical trials

195 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

195

registered trials across all phases

LATEST COMPLETION 2026

Active studies

Recruiting

Late-stage (III+)

Completed

Discontinued

PHASE DISTRIBUTIONn = 195

Early Phase 13Phase 117Phase 1 / 223Phase 267Phase 2 / 310Phase 343Phase 418Phase N / A14

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Prospective, Open-label, Controlled, Multiple Centers Clinical Study of the Efficacy and Safety for Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis (TAK): The VIVA-TAK Ttrial

Not yet recruitingPH IVChinese SLE Treatment And Research Groupn=1802029

Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout: A Randomized Controlled Trial

RecruitingPH IVMassachusetts General Hospitaln=6502028

A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis

RecruitingPH IVShanghai Zhongshan Hospitaln=1242027

The Impact of Prednisone on Semen Parameters and Pregnancy Rates Post Vasectomy Reversal: A Randomized, Controlled Trial

Active, not recruitingPH IVCharitable Union for the Research and Education of Peyronie's Diseasen=1002026

Glucocorticosteroid Treatment in Acute Unilateral Vestibulopathy, a Multicentric, Randomized, Double-blind, Placebo-controlled Study

CompletedPH IVUniversity Hospital, Genevan=962021

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression

CompletedPH IISeagen, a wholly owned subsidiary of Pfizern=822026

A Phase 2 Study of Nivolumab in Combination With Either Rucaparib, Docetaxel, or Enzalutamide in Men With Castration-resistant Metastatic Prostate Cancer

CompletedPH IIBristol-Myers Squibbn=2922025

The Effect of Low Doses of Intermediate Acting Corticosteroids on the Prolongation of Pregnancy in Threatened Preterm Birth

CompletedPH II/IIIUniversity of Mostarn=262024

SHR0302 and Prednisone As First Line Therapy for Chronic Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation

CompletedPH IShanghai General Hospital, Shanghai Jiao Tong University School of Medicinen=282024

Prospective, Multi-center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-Cell Lymphomas

CompletedPH I/IIUniversity of Chicagon=552024

A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination With Docetaxel, in Men With Metastatic Castration-resistant Prostate Cancer

CompletedPH IIIKey trialBristol-Myers Squibbn=1,0302024

Research activity

10 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time

20002025

Most influential

Abiraterone in metastatic prostate cancer without previous chemotherapy.

The New England journal of medicine · 2013 · 2,073 cites

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.

The New England journal of medicine · 2022 · 677 cites

Randomized Trial of Thymectomy in Myasthenia Gravis.

The New England journal of medicine · 2016 · 593 cites

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.

Blood · 2014 · 486 cites

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.

The New England journal of medicine · 2019 · 439 cites

Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination.

Journal of neurology, neurosurgery, and psychiatry · 2018 · 424 cites

Related diseases

2 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Active research areas

Neoplasm Metastasis2 Prostatic Neoplasms, Castration-Resistant2

Related drugs

8 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Cyclophosphamide

Studied across 10 of the same disease areas as Prednisone in the shared literature.

10 shared diseases2 shared papers

Doxorubicin

Studied across 9 of the same disease areas as Prednisone in the shared literature.

9 shared diseases2 shared papers

Vincristine

Studied across 9 of the same disease areas as Prednisone in the shared literature.

9 shared diseases2 shared papers

Bendamustine Hydrochloride

Studied across 8 of the same disease areas as Prednisone in the shared literature.

8 shared diseases1 shared paper

Mycophenolic Acid

Studied across 5 of the same disease areas as Prednisone in the shared literature.

5 shared diseases1 shared paper

Abiraterone Acetate

Studied across 3 of the same disease areas as Prednisone in the shared literature.

3 shared diseases2 shared papers

Abiraterone

Studied across 3 of the same disease areas as Prednisone in the shared literature.

3 shared diseases1 shared paper

Enzalutamide

Studied across 3 of the same disease areas as Prednisone in the shared literature.

3 shared diseases1 shared paper

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
Europe PMC — research literature
ClinicalTrials.gov — clinical trials
Regulatory event sources are credited in the Regulatory Timeline above.